489 Elucidate the underlying molecular mechanisms of the combination treatment effects of Afatinib (EGFR/HER2 inhibitor) and Crizotinib (MET inhibitor) in cutaneous malignant melanoma (CMM)

I. Das,H. Chen,Gianluca Maddalo,Margareta T. Wilhelm,Rainer Tuominen,Veronica Höiom,Johan Hansson,M. Davies,Suzanne Egyhazi Brage

489 Elucidate the underlying molecular mechanisms of the combination treatment effects of Afatinib (EGFR/HER2 inhibitor) and Crizotinib (MET inhibitor) in cutaneous malignant melanoma (CMM)

2019

I. Das
H. Chen
Gianluca Maddalo
Margareta T. Wilhelm
Rainer Tuominen
Veronica Höiom
Johan Hansson
M. Davies
Suzanne Egyhazi Brage

Elucidate the underlying molecular mechanisms of the combination treatment effects of Afatinib (EGFR/HER2 inhibitor) and Crizotinib (MET inhibitor) in cutaneous malignant melanoma (CMM)

Keywords:

Afatinib
Melanoma
Cancer research
Immunology
Biology
Crizotinib
combined treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations